We have located links that may give you full text access.
Journal Article
Review
Long-term outcomes in survivors of childhood acute lymphoblastic leukemia.
Hematology/oncology Clinics of North America 2009 October
Cure rates for childhood acute lymphoblastic leukemia (ALL) now exceed 80%. Consequently, there is a growing population of survivors of childhood ALL who are at risk for developing late sequelae of their cancer therapy. The risk of developing a late effect of therapy is particularly high in those survivors treated with cranial radiation or hematopoietic stem cell transplantation; however, most children who survive after treatment in the current era are expected to live normal lives with minimal or no longterm morbidity. In this article, the more common, serious late effects of ALL therapy are reviewed, the treatment exposures that predispose some survivors to their development are discussed, and the need for life-long risk-based medical care for all survivors of childhood ALL is emphasized.
Full text links
Related Resources
Trending Papers
A Guide to the Use of Vasopressors and Inotropes for Patients in Shock.Journal of Intensive Care Medicine 2024 April 14
British Society for Rheumatology guideline on management of adult and juvenile onset Sjögren disease.Rheumatology 2024 April 17
Albumin: a comprehensive review and practical guideline for clinical use.European Journal of Clinical Pharmacology 2024 April 13
Renin-Angiotensin-Aldosterone System: From History to Practice of a Secular Topic.International Journal of Molecular Sciences 2024 April 5
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app